10561 related articles for article (PubMed ID: 10232365)
21. Cloning and characterization of the genes encoding the murine homologues of the human melanoma antigens MART1 and gp100.
Zhai Y; Yang JC; Spiess P; Nishimura MI; Overwijk WW; Roberts B; Restifo NP; Rosenberg SA
J Immunother; 1997 Jan; 20(1):15-25. PubMed ID: 9101410
[TBL] [Abstract][Full Text] [Related]
22. Hydrodynamic limb vein delivery of a xenogeneic DNA cancer vaccine effectively induces antitumor immunity.
Neal ZC; Bates MK; Albertini MR; Herweijer H
Mol Ther; 2007 Feb; 15(2):422-30. PubMed ID: 17235322
[TBL] [Abstract][Full Text] [Related]
23. Immunizing patients with metastatic melanoma using recombinant adenoviruses encoding MART-1 or gp100 melanoma antigens.
Rosenberg SA; Zhai Y; Yang JC; Schwartzentruber DJ; Hwu P; Marincola FM; Topalian SL; Restifo NP; Seipp CA; Einhorn JH; Roberts B; White DE
J Natl Cancer Inst; 1998 Dec; 90(24):1894-900. PubMed ID: 9862627
[TBL] [Abstract][Full Text] [Related]
24. Granulocyte-macrophage-colony-stimulating factor added to a multipeptide vaccine for resected Stage II melanoma.
Weber J; Sondak VK; Scotland R; Phillip R; Wang F; Rubio V; Stuge TB; Groshen SG; Gee C; Jeffery GG; Sian S; Lee PP
Cancer; 2003 Jan; 97(1):186-200. PubMed ID: 12491520
[TBL] [Abstract][Full Text] [Related]
25. Induction of a systemic immune response by a polyvalent melanoma-associated antigen DNA vaccine for prevention and treatment of malignant melanoma.
Tanaka M; Kaneda Y; Fujii S; Yamano T; Hashimoto K; Huang SK; Hoon DS
Mol Ther; 2002 Mar; 5(3):291-9. PubMed ID: 11863419
[TBL] [Abstract][Full Text] [Related]
26. Potent selection of antigen loss variants of B16 melanoma following inflammatory killing of melanocytes in vivo.
Sanchez-Perez L; Kottke T; Diaz RM; Ahmed A; Thompson J; Chong H; Melcher A; Holmen S; Daniels G; Vile RG
Cancer Res; 2005 Mar; 65(5):2009-17. PubMed ID: 15753401
[TBL] [Abstract][Full Text] [Related]
27. Analysis of antitumor activity elicited by vaccination with combinations of interleukin-12 DNA with gp100 DNA or the chemokine CCL21 in vivo.
Elzaouk L; Pavlovic J; Moelling K
Hum Gene Ther; 2006 Aug; 17(8):859-70. PubMed ID: 16942445
[TBL] [Abstract][Full Text] [Related]
28. Induction of antitumor immunity with dendritic cells transduced with adenovirus vector-encoding endogenous tumor-associated antigens.
Kaplan JM; Yu Q; Piraino ST; Pennington SE; Shankara S; Woodworth LA; Roberts BL
J Immunol; 1999 Jul; 163(2):699-707. PubMed ID: 10395660
[TBL] [Abstract][Full Text] [Related]
29. Mechanism of protection against influenza A virus by DNA vaccine encoding the hemagglutinin gene.
Operschall E; Pavlovic J; Nawrath M; Mölling K
Intervirology; 2000; 43(4-6):322-30. PubMed ID: 11251388
[TBL] [Abstract][Full Text] [Related]
30. Increased immunogenicity of tumor vaccines complexed with anti-Gal: studies in knockout mice for alpha1,3galactosyltransferase.
LaTemple DC; Abrams JT; Zhang SY; Galili U
Cancer Res; 1999 Jul; 59(14):3417-23. PubMed ID: 10416604
[TBL] [Abstract][Full Text] [Related]
31. Single-step antigen loading and activation of dendritic cells by mRNA electroporation for the purpose of therapeutic vaccination in melanoma patients.
Bonehill A; Van Nuffel AM; Corthals J; Tuyaerts S; Heirman C; François V; Colau D; van der Bruggen P; Neyns B; Thielemans K
Clin Cancer Res; 2009 May; 15(10):3366-75. PubMed ID: 19417017
[TBL] [Abstract][Full Text] [Related]
32. Peptide vaccination of patients with metastatic melanoma: improved clinical outcome in patients demonstrating effective immunization.
Markovic SN; Suman VJ; Ingle JN; Kaur JS; Pitot HC; Loprinzi CL; Rao RD; Creagan ET; Pittelkow MR; Allred JB; Nevala WK; Celis E
Am J Clin Oncol; 2006 Aug; 29(4):352-60. PubMed ID: 16891861
[TBL] [Abstract][Full Text] [Related]
33. Mannose receptor targeting of tumor antigen pmel17 to human dendritic cells directs anti-melanoma T cell responses via multiple HLA molecules.
Ramakrishna V; Treml JF; Vitale L; Connolly JE; O'Neill T; Smith PA; Jones CL; He LZ; Goldstein J; Wallace PK; Keler T; Endres MJ
J Immunol; 2004 Mar; 172(5):2845-52. PubMed ID: 14978085
[TBL] [Abstract][Full Text] [Related]
34. Adoptive T cell immunotherapy of human uveal melanoma targeting gp100.
Sutmuller RP; Schurmans LR; van Duivenvoorde LM; Tine JA; van Der Voort EI; Toes RE; Melief CJ; Jager MJ; Offringa R
J Immunol; 2000 Dec; 165(12):7308-15. PubMed ID: 11120866
[TBL] [Abstract][Full Text] [Related]
35. Immunogene therapy for murine melanoma using recombinant adenoviral vectors expressing melanoma-associated antigens.
Perricone MA; Claussen KA; Smith KA; Kaplan JM; Piraino S; Shankara S; Roberts BL
Mol Ther; 2000 Mar; 1(3):275-84. PubMed ID: 10933943
[TBL] [Abstract][Full Text] [Related]
36. T-cell clones from melanoma patients immunized against an anchor-modified gp100 peptide display discordant effector phenotypes.
Dudley ME; Ngo LT; Westwood J; Wunderlich JR; Rosenberg SA
Cancer J; 2000; 6(2):69-77. PubMed ID: 11069222
[TBL] [Abstract][Full Text] [Related]
37. Identification of a novel gp100/pMel17 peptide presented by HLA-A*6801 and recognized on human melanoma by cytolytic T cell clones.
Sensi M; Pellegatta S; Vegetti C; Nicolini G; Parmiani G; Anichini A
Tissue Antigens; 2002 Apr; 59(4):273-9. PubMed ID: 12135425
[TBL] [Abstract][Full Text] [Related]
38. Recognition of multiple epitopes in the human melanoma antigen gp100 by peripheral blood lymphocytes stimulated in vitro with synthetic peptides.
Salgaller ML; Afshar A; Marincola FM; Rivoltini L; Kawakami Y; Rosenberg SA
Cancer Res; 1995 Nov; 55(21):4972-9. PubMed ID: 7585538
[TBL] [Abstract][Full Text] [Related]
39. Bone marrow-derived dendritic cell vaccination of dogs with naturally occurring melanoma by using human gp100 antigen.
Gyorffy S; Rodriguez-Lecompte JC; Woods JP; Foley R; Kruth S; Liaw PC; Gauldie J
J Vet Intern Med; 2005; 19(1):56-63. PubMed ID: 15715049
[TBL] [Abstract][Full Text] [Related]
40. Murine responses to recombinant MVA versus ALVAC vaccines against tumor-associated antigens, gp100 and 5T4.
Hanwell DG; McNeil B; Visan L; Rodrigues L; Dunn P; Shewen PE; Macallum GE; Turner PV; Vogel TU
J Immunother; 2013 May; 36(4):238-47. PubMed ID: 23603858
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
